Alosetron: An effective treatment for diarrhea-predominant irritable bowel syndrome

Lucinda A. Harris, Lin Chang

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Serotonin (5-HT) is one of the key mediators of gut motility, secretion and sensation. Most 5-HT is localized in the gastrointestinal tract. Particularly important for gut function and regulation are the 5-HT1p, 5-HT3 and 5-HT4 receptors. These receptors have been the focus of research evaluating the pathophysiologic mechanisms of irritable bowel syndrome (IBS) as well as targets for the development of novel agents to treat irritable bowel syndrome. Alosetron is one of three 5-HT3 antagonists currently available. The other two, ondansetron and granisetron, are primarily used in the treatment of chemotherapy-induced nausea and vomiting. Alosetron, which slows gut transit, has been approved for the treatment of severe diarrhea-predominant IBS (IBS-D) in women. This review will examine the common, yet therapeutically challenging, disorder IBS, as well as the role of alosetron in the treatment of IBS-D.

Original languageEnglish (US)
Pages (from-to)15-27
Number of pages13
JournalWomen's Health
Volume3
Issue number1
DOIs
StatePublished - Jan 2007

Fingerprint

Irritable Bowel Syndrome
Diarrhea
Serotonin
Therapeutics
Receptors, Serotonin, 5-HT4
Granisetron
Serotonin 5-HT3 Receptor Antagonists
Ondansetron
Nausea
Vomiting
Gastrointestinal Tract
alosetron
Drug Therapy
Research

Keywords

  • 5-HT3-antagonists
  • Alosetron
  • Irritable bowel syndrome

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Alosetron : An effective treatment for diarrhea-predominant irritable bowel syndrome. / Harris, Lucinda A.; Chang, Lin.

In: Women's Health, Vol. 3, No. 1, 01.2007, p. 15-27.

Research output: Contribution to journalArticle

Harris, Lucinda A. ; Chang, Lin. / Alosetron : An effective treatment for diarrhea-predominant irritable bowel syndrome. In: Women's Health. 2007 ; Vol. 3, No. 1. pp. 15-27.
@article{24ad7bf1362c4361b2d71517c3c999c1,
title = "Alosetron: An effective treatment for diarrhea-predominant irritable bowel syndrome",
abstract = "Serotonin (5-HT) is one of the key mediators of gut motility, secretion and sensation. Most 5-HT is localized in the gastrointestinal tract. Particularly important for gut function and regulation are the 5-HT1p, 5-HT3 and 5-HT4 receptors. These receptors have been the focus of research evaluating the pathophysiologic mechanisms of irritable bowel syndrome (IBS) as well as targets for the development of novel agents to treat irritable bowel syndrome. Alosetron is one of three 5-HT3 antagonists currently available. The other two, ondansetron and granisetron, are primarily used in the treatment of chemotherapy-induced nausea and vomiting. Alosetron, which slows gut transit, has been approved for the treatment of severe diarrhea-predominant IBS (IBS-D) in women. This review will examine the common, yet therapeutically challenging, disorder IBS, as well as the role of alosetron in the treatment of IBS-D.",
keywords = "5-HT3-antagonists, Alosetron, Irritable bowel syndrome",
author = "Harris, {Lucinda A.} and Lin Chang",
year = "2007",
month = "1",
doi = "10.2217/17455057.3.1.15",
language = "English (US)",
volume = "3",
pages = "15--27",
journal = "Women's health (London, England)",
issn = "1745-5065",
publisher = "Future Medicine Ltd.",
number = "1",

}

TY - JOUR

T1 - Alosetron

T2 - An effective treatment for diarrhea-predominant irritable bowel syndrome

AU - Harris, Lucinda A.

AU - Chang, Lin

PY - 2007/1

Y1 - 2007/1

N2 - Serotonin (5-HT) is one of the key mediators of gut motility, secretion and sensation. Most 5-HT is localized in the gastrointestinal tract. Particularly important for gut function and regulation are the 5-HT1p, 5-HT3 and 5-HT4 receptors. These receptors have been the focus of research evaluating the pathophysiologic mechanisms of irritable bowel syndrome (IBS) as well as targets for the development of novel agents to treat irritable bowel syndrome. Alosetron is one of three 5-HT3 antagonists currently available. The other two, ondansetron and granisetron, are primarily used in the treatment of chemotherapy-induced nausea and vomiting. Alosetron, which slows gut transit, has been approved for the treatment of severe diarrhea-predominant IBS (IBS-D) in women. This review will examine the common, yet therapeutically challenging, disorder IBS, as well as the role of alosetron in the treatment of IBS-D.

AB - Serotonin (5-HT) is one of the key mediators of gut motility, secretion and sensation. Most 5-HT is localized in the gastrointestinal tract. Particularly important for gut function and regulation are the 5-HT1p, 5-HT3 and 5-HT4 receptors. These receptors have been the focus of research evaluating the pathophysiologic mechanisms of irritable bowel syndrome (IBS) as well as targets for the development of novel agents to treat irritable bowel syndrome. Alosetron is one of three 5-HT3 antagonists currently available. The other two, ondansetron and granisetron, are primarily used in the treatment of chemotherapy-induced nausea and vomiting. Alosetron, which slows gut transit, has been approved for the treatment of severe diarrhea-predominant IBS (IBS-D) in women. This review will examine the common, yet therapeutically challenging, disorder IBS, as well as the role of alosetron in the treatment of IBS-D.

KW - 5-HT3-antagonists

KW - Alosetron

KW - Irritable bowel syndrome

UR - http://www.scopus.com/inward/record.url?scp=33846522880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846522880&partnerID=8YFLogxK

U2 - 10.2217/17455057.3.1.15

DO - 10.2217/17455057.3.1.15

M3 - Article

C2 - 19803861

AN - SCOPUS:33846522880

VL - 3

SP - 15

EP - 27

JO - Women's health (London, England)

JF - Women's health (London, England)

SN - 1745-5065

IS - 1

ER -